Updated on 9 February 2017
OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces the closure of their Series B financing. All Series A investors teamed up with a family office and jointly invested in OrthoSera GmbH in order to fund clinical studies with hypACT.
"We are very pleased with the continued support of our lead investor FastVentures, who together with Euroventures and Futurmed were instrumental in closing this oversubscribed financing round" says Björn Ehring, CFO of OrthoSera. "Futurmed has established a large portfolio of healthcare services investments in the region and their support signals OrthoSera's move into clinical development".
After the successful launch of BoneAlbumin in 2015, OrthoSera is introducing its next innovative serum-based product to the market. hypACT, a novel hyperacute serum has shown very positive effects compared to PRP and other blood derivatives in ex vivo osteoarthritic human tissues.
This patent-covered serum extraction is currently being clinically administered in Europe with OrthoSera's CE-marked autologous hypACT Inject device. The initial indication of hypACT is regeneration of articular tissues, including cartilage and bone in the knee for the treatment of osteoarthritis patients. Clinical data is being gathered through a number of key opinion leaders in the field.
"Serum therapies are on the rise and will be the next wave of orthobiologics in the coming years. OrthoSera has already shown with BoneAlbumin that serum addition has a very tangible clinical benefit in bone grafting, and we are thrilled to see how we can extend our therapeutic reach to the joint space with hypACTTM" says Dr. Zsombor Lacza, Founder and CEO.